Inactive Instrument

Analyst Reco. Sartorius Stedim Biotech SA Euronext Paris

Equities

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-

Apr. 23	SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	ZD
Apr. 22	Sartorius Stedim: in the red with brokerage comments	CF

SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	Apr. 23	ZD
Sartorius Stedim: in the red with brokerage comments	Apr. 22	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	Apr. 22	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	Apr. 22
SARTORIUS STEDIM : UBS reduces target price	Apr. 22	CF
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	Mar. 12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	Feb. 16	MT
SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’	Jan. 30
SARTORIUS STEDIM : UBS raises its target price	Jan. 29	CF
Sartorius thwarted by 21-day line - despite HSBC recommendation	Jan. 10	DP
JPMORGAN : Sartorius outlook likely to be share price driver	Jan. 02	DP
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	Dec. 19
Sartorius continues to slide - low since April 2020	23-10-23	DP
Sartorius and subsidiary recover - JPMorgan praises biotech orders	23-10-19	DP
SARTORIUS STEDIM BIOTECH : Disappointing preliminary Q3 23 puts mid-term outlook in question	23-10-17
Profit warning weighs heavily on Sartorius and subsidiary Stedim	23-10-13	DP
SARTORIUS STEDIM BIOTECH : Jefferies reiterates its Buy rating	23-09-29	ZD
Chinese headwinds could be more severe than expected	23-09-22
German Stocks Extend Losses Amid Rate Jitters Ahead of Monetary Policy Week	23-09-08	MT
SARTORIUS STEDIM BIOTECH : Jefferies gives a Buy rating	23-09-06	ZD

No results for this search

SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss

April 22, 2024 at 07:56 am EDT